Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Acadia Healthcare Company Inc (ACHC) vs Cassava Sciences Inc (FLNA) Price & Performance

Acadia Healthcare Company Inc
Cassava Sciences Inc

Price performance

Price movement over the last 24 hours

Key statistics

Acadia Healthcare Company Inc vs Cassava Sciences Inc — how do they compare? Acadia Healthcare Company Inc trades at $30.74 (market cap $2.94B), while Cassava Sciences Inc trades at $1.25 (market cap $63.04M). The key difference: Acadia Healthcare Company Inc is far larger — about 46.6× Cassava Sciences Inc's market cap, and Acadia Healthcare Company Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

ACHCFLNA
Market Cap
$2.94B$63.04M
Sector
HealthHealth
52-Week High
$31.92$4.64
52-Week Low
$11.68$1.16
Enterprise Value
$5.45B-$23.53M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Acadia Healthcare Company Inc

ACHC trades at $31.09, down 2.57% today but maintains a bullish technical outlook with strong moving average support. The company shows operational strength with three consecutive earnings beats, though profitability remains challenged with a -32.84% net margin. Analyst consensus is strongly bullish with 68% buy ratings, while recent news highlights the company's strategic shift toward profitability and rising behavioral health demand.

The stock presents a mixed opportunity with strong technical momentum and analyst support offset by persistent profitability challenges. Key catalysts include continued earnings outperformance and successful execution of the turnaround strategy, while risks center on margin pressures and high short interest that could limit upside potential.

Cassava Sciences Inc

FLNA trades at $1.31, up 6.5% today, with a bearish technical signal but recent quarterly earnings beats. The company, focused on therapies for Tuberous Sclerosis Complex-related epilepsy, reported a net loss of $90.97 million in 2025, with negative cash flow from operations. Analyst consensus is bullish with 8 buy ratings out of 12, and recent news highlights business updates and scientific presentations.

The outlook is mixed: strong analyst support and clinical progress offer upside potential, but persistent losses, negative cash flow, and high financial risks pose significant challenges. Investors should weigh the speculative growth prospects against the substantial operational deficits and market volatility.

Returns comparison

Trailing returns across standard periods

About Acadia Healthcare Company Inc

Acadia Healthcare is a leading provider of behavioral healthcare services across the US and Puerto Rico. It operates a network of psychiatric hospitals, residential treatment centers, and clinics for mental health and addiction recovery.

Read more on ACHC

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA